替代品
发表于 2025-3-25 05:43:20
http://reply.papertrans.cn/64/6311/631065/631065_21.png
有权
发表于 2025-3-25 09:57:16
http://reply.papertrans.cn/64/6311/631065/631065_22.png
labile
发表于 2025-3-25 13:26:47
http://reply.papertrans.cn/64/6311/631065/631065_23.png
愤慨点吧
发表于 2025-3-25 17:43:35
Genetics and Epigenetics of Mesothelioma,ents. These patients are more sensitive to asbestos exposure than those who do not carry such mutations and may benefit of specific treatments. Additionally, epigenetic mechanisms, such as methylation or miRNA alterations, may modify gene expression and drive carcinogenesis. The same abnormalities m
雇佣兵
发表于 2025-3-25 22:23:44
http://reply.papertrans.cn/64/6311/631065/631065_25.png
不遵守
发表于 2025-3-26 02:49:07
Pathological Diagnosis of Mesothelioma, between benign and malignant mesothelial proliferations..This chapter is an update of the morphological, immunohistochemical, and molecular features, with particular regard to diffuse malignant mesothelioma diagnosis.
男学院
发表于 2025-3-26 04:24:54
http://reply.papertrans.cn/64/6311/631065/631065_27.png
要求比…更好
发表于 2025-3-26 10:47:03
Role of Metabolic Imaging in Mesothelioma,characterized by the worst prognosis. PET-CT is gradually becoming essential in assessment of tumour response in patients undergoing chemotherapy. Metabolic imaging analysis permits the early identification of non-responders to chemotherapy, avoiding unsuccessful treatment, characterized by importan
补助
发表于 2025-3-26 15:49:12
Surgery and Multimodality Treatment in Malignant Pleural Mesothelioma,ideration..Individualization of care for each patient is mandatory in choosing the most appropriate treatment to minimize the complications and to maximize the benefits..The aim of this chapter is to give an overview on the current state of multimodality treatment in MPM.
摊位
发表于 2025-3-26 20:34:11
Role of Chemotherapy in the Management of Malignant Pleural Mesothelioma,cond-line setting, if clinical trials are not available, single-agent therapy with vinorelbine or gemcitabine may be considered. Alternatively, patients achieving a prolonged benefit from first-line pemetrexed-platinum treatment may be candidate to rechallenge with pemetrexed-based regimens.